FOLH1 and prostate carcinoma: Therefore, PSMA-targeting agents including aptamers [14,15], antibodies [16], peptides [17], and small molecule inhibitors [18] have been extensively studied and applied to small molecule drug conjugates [19,20,21] and nanomedicines [22,23,24,25] for diagnosis and treatment in prostate cancer.